1stOncology™: Cancer Intelligence Service – Page 11446 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

We have surpassed our €1.2M target in the latest round of financing

On November 24, 2020 Laminar Pharma reported that closer and closer to our stock market launch (Press release, Laminar Pharma, NOV 24, 2020, View Source [SID1234574077]). That’s why we launched a funding round this month to increase investment in research staff and advance the development of clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

This operation raised more than 1.2 million euros

The financing round was launched on October 30 with the aim of raising 1.2 million euros and is currently available on the Fellow Funders Crowd Investment platform. In the first two weeks, thanks to the trust of numerous investors, more than one million euros had been raised, which is equivalent to 92% of the target set and now, before the month ends the target will be met. In addition to this main source of financing, which is private investment, we have received support from the Spanish government, Spain’s regional governments and the European Commission.

Pablo Escribá, our CEO, has a positive outlook: "We are happy about exceeding the planned target, as we did in the round at the end of last year. Currently at Laminar Pharma we hold patents for 8% of all drugs under development by Spanish biotechnology companies in our country, according to the pipeline of the Spanish Association of Bio-companies (ASEBIO) and we hope to grow in valuation as we advance in the clinical research stages of our drugs undergoing development. The company plans to request marketing authorization from regulatory agencies in two years, with the aim of announcing our first market launch in 2023."

Fellow Funders partner Mariano Colmenar is satisfied with the operation, which is run by his own collective financing platform, authorized and supervised by the National Securities Market Commission (CNMV) since 2016. "We have shown that investors see a promising future in the biotechnology sector, anticipating good benefits. The pharmaceutical market is a long-term market, since years of research and clinical trials are necessary before the products can safely be launched to market." Fellow Funders collaborates with Nowture, the first comprehensive ecosystem that catalyzes and drives the growth of the Biotechnology and Life Sciences sector in Spain, offering a model of specialized and customized services, with national and European science and business experts. Nowture company, was born at the end of 2020 as the first comprehensive investment and promotion ecosystem for companies in the Biotechnology and life sciences sector in Spain. Nowture has been present in Laminar Pharma’s capital since 2019, to accompany it in the optimization and execution of the product development plan, in the corporate financing strategy and in its preparation to apply to join BME Growth.

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

On November 24, 2020 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that management will present at two upcoming virtual investor conferences in December (Press release, Protara Therapeutics, NOV 24, 2020, View Source [SID1234573139]):

Piper Sandler 32nd Annual Virtual Healthcare Conference
Evercore ISI 3rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020 at 12:10pm ET
A webcast of the live Evercore presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source A replay of the pre-recorded Piper fireside chat is currently available on the Company’s website. The webcasts will be archived on the Company’s website for 90 days following the presentation.

NICE backs Braftovi for BRAF-positive colorectal cancer

On November 24, 2020 Pierre Fabre reported that The National Institute for Health and Care Excellence (NICE) has back Braftovi plus cetuximab for the treatment of BRAF-positive metastatic colorectal cancer (Press release, PharmaTimes, NOV 24, 2020, View Source [SID1234571775]).

In September, NICE initially turned down Braftovi (encorafenib) after finding that the cost-effectiveness estimates were higher than what is normally considered value for money for the NHS.

However, NICE has now decided to recommend the drug in combination with cetuximab for BRAF V600E mutation-positive metastatic colorectal cancer (mCRC) in adults who have had previous systemic treatment.

The NICE decision is based on results from the phase III BEACON CRC trial, which showed that Braftovi plus cetuximab significantly improved median overall survival in patients with BRAF V600E-mutated mCRC and reduced the risk of death by 39%.

The combination treatment also produced an improved objective response rate compared to the control arm.

"We are delighted that NICE has recognised the value of Braftovi plus cetuximab for this high medical-need population," said Laura McMullin, general manager UK & Ireland, Pierre Fabre.

"Securing NHS reimbursement is the culmination of collaborative discussions that we have been having with NICE and NHS England since the end of last year.

"In particular, we would like to recognise the efforts of NHS England who have consistently supported appropriate access for this treatment. The result underscores our commitment to the colorectal cancer community and we hope that as many people as possible will benefit from this innovative treatment," she added.

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

On November 24, 2020 vTv Therapeutics Inc. (Nasdaq: VTVT) reported it has entered into a common stock purchase agreement ("Purchase Agreement") for up to $47 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor (Press release, vTv Therapeutics, NOV 24, 2020, View Source [SID1234571746]).

"The LPC financing will help us reach a number of potential value-driving events over the next six to nine months, including the upcoming topline results of our phase 2 Elevage Study in patients with Alzheimer’s disease and type 2 diabetes in December," said Steve Holcombe, President and CEO of vTv Therapeutics. "In addition, these funds will help us conduct a mechanistic study of TTP399, our oral treatment for patients with type 1 diabetes focused on its impact on diabetic ketoacidosis, and additionally a multiple-ascending dose study of HPP737 as a potential oral treatment for psoriasis."

vTv will have the option, but not the obligation, to sell to LPC up to $47.0 million in shares of Class A common stock over a thirty-six-month period subject to certain conditions, including a registration statement being filed and declared effective by the SEC. There are no upper limits to the price LPC may pay to purchase Class A common stock from vTv and the purchase price of the shares will be based on the prevailing market prices of vTv’s shares at the time of each sale to LPC.

LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of vTv’s shares of Class A common stock. No warrants, derivatives, or other share classes are associated with this agreement. In consideration for entering into the agreement, vTv has issued shares of Class A common stock to LPC as a commitment fee. The Purchase Agreement may be terminated by vTv at any time, at its sole discretion, without any additional cost or penalty.

vTv intends to use the net proceeds from the transaction for general corporate purposes and to support its clinical development strategy, including finalizing and reporting topline results from the Company’s ongoing Elevage Study of azeliragon for the treatment of Alzheimer’s disease in patients with type 2 diabetes in December 2020, conducting a mechanistic study of TTP399 in patients with type 1 diabetes, and conducting a multiple-ascending dose study of HPP737 as part of a development program of the product as an oral therapy for psoriasis.

A more detailed description of the agreement is set forth in vTv’s Current Report on Form 8-K to be filed with the SEC.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

On November 24, 2020 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences (Press release, Savara, NOV 24, 2020, View Source [SID1234571745]):

Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/.
Evercore ISI Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 PM EST/9:35 AM PST. A live webcast will be available on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect at least 15 minutes prior to the start of the event to ensure sufficient time for any software download that may be required.
Replays of both events will remain available on Savara’s website for 90 days.